Side-by-side comparison of AI visibility scores, market position, and capabilities
INBRAIN Neuroelectronics develops graphene-based brain-computer interfaces for AI-driven, adaptive neuromodulation; raised €30M Series B in 2024; targeting Parkinson's, epilepsy, and psychiatric disorders;
INBRAIN Neuroelectronics is a neurotechnology company founded in 2019 as a spin-out from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, Spain. The company develops minimally invasive brain-computer interfaces built on graphene — a single layer of carbon atoms with exceptional electrical conductivity, biocompatibility, and transparency to MRI imaging. INBRAIN's graphene electrodes enable higher spatial resolution neural sensing and more precise, adaptive stimulation than conventional metal electrodes used in implantable neurostimulators.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.